REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.18
+0.21 (2.63%)
May 13, 2025, 4:00 PM - Market closed
REGENXBIO Employees
REGENXBIO had 353 employees as of December 31, 2024. The number of employees increased by 9 or 2.62% compared to the previous year.
Employees
353
Change (1Y)
9
Growth (1Y)
2.62%
Revenue / Employee
$443,960
Profits / Employee
-$446,711
Market Cap
410.31M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RGNX News
- 1 day ago - REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II - PRNewsWire
- 1 day ago - REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights - PRNewsWire
- 6 days ago - REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting - PRNewsWire
- 8 days ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 13 days ago - REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights - PRNewsWire
- 6 weeks ago - 5 Reasons To Buy Regenxbio Right Now - Seeking Alpha
- 7 weeks ago - REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY - PRNewsWire